Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2500-2504

  Loehrer Sr , Patrick J ^a   Gonin, René ^b   Nichols, Craig R ^b   Weathers, Tess ^b   Einhorn, Lawrence H ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; IFOSFAMIDE; VINBLASTINE;

ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; GERM CELL TUMOR; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0344734200     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2500     Document Type: Article

References (19)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981
2. Williams SD, Einhorn LH, Greco FA, et al: VP-16-213 salvage therapy tor refractory germinal neoplasms. Cancer 46:2154-2158, 1980
3. Hainsworth JD, Williams SD, Einhorn LH, et al: Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: Results of a Southeastern Cancer Study Group trial. J Clin Oncol 3:666-671, 1985
4. Schabel FM, Jr, Trader MW, Laster WR, Jr, et al: Cisdichlorodiammineplatinum: Combination chemotherapy and cross-resistance studies with tumor of mice. Cancer Treat Rep 63:1459-1473, 1979
5. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 3116:1435-1440, 1987
6. Wheeler BM, Loehrer PJ, Williams SD, et al: Ifosfamide in refractory germ cell tumors. J Clin Oncol 4:28-34, 1986
7. Loehrer PJ, Einhorn LH, Williams SD: Salvage therapy for refractory germ cell tumors with VP-16 + Ifosfamide + cisplatin. J Clin Oncol 4:528-536, 1986
8. Birch R, Williams SD, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Armitage P, Berry G: Statistical Methods in Medical Research (ed 2) Oxford United Kingdom, Blackwell, 1987, pp 427-428
11. Schmoll HJ: The role of ifosfamide in testicular cancer. Semin Oncol 16:82-93, 1989
12. Droz JP, Ribrag V, Ghosn M, et al: Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory, in NY, Murphy G, Ghovry S (eds): Therapeutic Progress in Urological Cancers. New York, NY, Alan R. Liss, 1989, pp 739-747
13. Motzer RJ, Cooper K, Geller NL, et al: The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476-2481, 1990
14. Garnick MB, Canellos GP, Richie JP: Treatment and surgical staging of testicular and primary extragonadal germ cell cancer. JAMA 250:1733-1741, 1983
15. Motzer ZRJ, Geller NL, Tan C, et al: Salvage chemotherapy for patients with germ cell tumors. Cancer 67:1305-1310, 1991
16. Saxman S, Nichols CR, Einhorn LH: Salvage chemotherapy in patients with extragonadal germ cell tumors: The Indiana University experience. J Clin Oncol 12:1390-1393, 1994
17. Brock N, Hilgard P, Pohl J, et al: Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol 108:87-97, 1984
18. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
19. Broun ER, Nichols CR, Gize G, et al: Tandem high dose therapy with autologous bone marrow transplantation for initial relapse of germ cell cancer. Cancer 79:1605-1610, 1997